Activity content starts in:
Virtual CME Program
1.00 CME/CE Credit
Entering a New Age of MASH: Classifying, Risk-Stratifying, and Managing Metabolic Dysfunction-Associated Steatohepatitis
Join us for an exciting session led by a hepatology expert exploring the latest advances in steatotic liver disease (SLD). Gain insights into new nomenclature, diagnostic criteria, and the natural history of MASLD and MASH. Learn how to implement noninvasive tools for risk stratification and management, and apply guideline-directed treatments to optimize patient outcomes.
CME/CE Information
1.00 AMA PRA Category 1 Credits™, 1.00 ABIM MOC or 1.00 AANP, including 0.25 AANP Pharm
Release Date: 12/12/2024
Expiration Date: 12/12/2025
Topics
Learning Objectives
- Describe the new nomenclature and diagnostic criteria for steatotic liver disease
- Discuss the natural history, risk factors, cardiometabolic comorbidities, and potential health consequences of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH)
- Utilize noninvasive tools for the risk stratification, management, and monitoring of patients with MASLD and MASH
- Apply current guideline-directed treatment of MASLD and MASH, with a focus on risk factor reduction and management of comorbid conditions
Faculty
Charles Vega, MD, FAAFP
Health Sciences Clinical Professor, UC Irvine Department of Family Medicine, Assistant Dean for Culture and Community Education, UC Irvine School of Medicine
Executive Director, UC Irvine Program in Medical Education for the Latino Community, UC Irvine School of Medicine
Sammy Saab, MD, MPH, AGAF, FACG, FAASLD
Professor, Medicine and Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California
Head, Outcomes Research in Hepatology, David Geffen School of Medicine at UCLA, Los Angeles, California
Disclosures
The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
Charles Vega, MD, FAAFP: No relevant financial relationships disclosed
Sammy Saab: Advisor for Madrigal
Moderator, non-faculty contributors and others involved in the planning, development, editing, and review of the content have disclosed no relevant financial relationships.
CME/CE Information
AMA PRA Category 1 Credits™
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and American Liver Foundation. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.
Designation Statement
Pri-Med Institute designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AANP
Accreditation Statement
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of Pri-Med Institute and American Liver Foundation. Pri-Med Institute is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider Number 040308.
Designation Statement
This activity is approved for 1.00 contact hour of continuing education, which includes 0.25 hours of pharmacology.
MOC Credit Information
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Obtaining Credit
Supporters and Partners
Supported by
Novo Nordisk Inc.
Education Partners
Pri-Med Institute
American Liver Foundation
Fine Print
The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions?
If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.